Biotechnology firm Pharming saw its losses increase to €6.4m in the first three months of 2008 due to problems with licencing its drug Rhucin in the US and Europe.
The company expects to submit a new file on Rhucin to the European medicines authority EMEA shortly.
The company said it is also focusing on getting the drug, which is used to treat hereditary angioedema, approved outside the EU.
Thank you for donating to DutchNews.nl.
We could not provide the Dutch News service, and keep it free of charge, without the generous support of our readers. Your donations allow us to report on issues you tell us matter, and provide you with a summary of the most important Dutch news each day.Make a donation